GSK plc (GLAXF)
Market Cap | 87.37B |
Revenue (ttm) | 43.34B |
Net Income (ttm) | 4.69B |
Shares Out | n/a |
EPS (ttm) | 1.13 |
PE Ratio | 18.63 |
Forward PE | 9.26 |
Dividend | 0.82 (3.91%) |
Ex-Dividend Date | Aug 14, 2025 |
Volume | 345 |
Average Volume | 4,670 |
Open | 21.74 |
Previous Close | 21.00 |
Day's Range | 21.74 - 21.74 |
52-Week Range | 15.54 - 22.85 |
Beta | 0.29 |
RSI | 56.78 |
Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews

Focus: US Health Secretary Kennedy speeds autism drug with GSK help
U.S. Health Secretary Robert F Kennedy Jr. could deliver a policy win for the Trump administration in just a few months after the Food and Drug Administration enlisted GSK to help it fast-track approv...
Top global stories this week: GSK, Hitachi, Tesco among notable names

Outgoing GSK boss Emma Walmsley takes swipe at Labour
Walmsley became the latest to speak out over a pricing regime that has infuriated the pharmaceutical sector.

FTSE 100 hits another high despite concerns over US government shutdown
Drug companies AstraZeneca, Hikma Pharmaceuticals and GSK were all big risers.

Market Voices: Cook vs. Trump, ADP job data, GSK CEO on drug talks
Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.
GSK's $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal
GSK's $30B US Gamble Sends Pharma Stocks Soaring After Trump Pricing Deal

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immuniz...

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

AnaptysBio Charts Path To Split Into Two Public Companies By 2026
AnaptysBio, Inc. (NASDAQ: ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies. Referred to as “Royalty Management Co” and “Biop...
GSK leadership shuffle: Luke Miels named CEO after Emma Walmsley exits; US tariffs test British pharma sector
GSK CEO Emma Walmsley will step down in January, with Luke Miels taking over amidst looming US tariffs on branded pharmaceutical imports. This leadership change comes as GSK navigates critical global ...
GSK Begins GBP 0.3 Bln Third Tranche Of GBP 2 Bln Share Buyback Programme
(RTTNews) - GSK plc (GSK, GSK.L), a biopharmaceutical company, on Tuesday said it has commenced the third tranche valued at up to 0.3 billion pounds of its previously announced 2 billion pounds share ...
GSK: Walmsley Out, Miels In - I'm Watching The CEO Transition From The Sidelines

Emma Walmsley steadied GSK – but doubts linger over growth targets
The outgoing chief executive reshaped the drugmaker, yet scepticism persists over promised revenues GSK’s Emma Walmsley to step down as chief executive after eight years “I am a change agent,” declare...
GSK (GSK) Shares Rise as Luke Miels Announced as Future CEO
GSK (GSK) Shares Rise as Luke Miels Announced as Future CEO
GSK Will Replace CEO Walmsley With a Company Insider. The Stock Is Up.

European stocks advance as pharma giants AstraZeneca and GSK notch gains
The U.K.'s FTSE 100 led gains on Monday.

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Wal...

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
GSK stock jumped back into a buy zone Monday after announcing Chief Executive Emma Walmsley will step down at the end of the year.
GSK (GSK) Announces Leadership Change as CEO Emma Walmsley Steps Down
GSK (GSK) Announces Leadership Change as CEO Emma Walmsley Steps Down

Analyst: Miels was always number one candidate for GSK CEO
GSK CEO Emma Walmsley will step down in January after nine years at the helm of the British drugmaker.She will be replaced by the current chief commercial officer, Luke Miels. Emily Field, Head of Eur...
GSK CEO Emma Walmsley to Step Down as Commercial Chief Takes Helm

GSK's Walmsley to step down early as insider Luke Miels named next CEO
GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday.
GSK CEO Emma Walmsley to Step Down, Luke Miels to Succeed
GSK CEO Emma Walmsley to Step Down, Luke Miels to Succeed